|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||147.30 - 149.80|
|52 Week Range||105.00 - 164.15|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||69.22|
|Forward Dividend & Yield||0.70 (0.47%)|
|Ex-Dividend Date||May 28, 2020|
|1y Target Est||N/A|
Today we are going to look at Dassault Systèmes SE (EPA:DSY) to see whether it might be an attractive investment...
A broad moat, multi-cylinder growth engine and recurring revenue model shed light on long-term shareholder value of the software business Continue reading...
France has enlisted tech companies Dassault Systemes and OVH to come up with plans to break the dominance of U.S. companies in cloud computing, its finance minister said on Thursday. Paris is eager to build up a capacity to store sensitive data in France amid concerns the U.S. government can obtain data kept on the servers of U.S. companies such as Amazon and Microsoft.
In 2002 Bernard Charlès was appointed CEO of Dassault Systèmes SE (EPA:DSY). This analysis aims first to contrast CEO...
(Bloomberg) -- French technology company Dassault Systemes SE agreed to buy Medidata Solutions Inc., a software firm that analyzes clinical trials, for $5.7 billion to bolster its offerings to the pharmaceutical industry.The record deal will allow Dassault to offer drugmakers a complete set of services and ride a shift toward personalized medicine, in which research and tools are tailored to individual patient profiles, generating the need to analyze vast amounts of data.Health is becoming a crucial market for Dassault, which also creates 3D design software, said Pascal Daloz, the company’s chief financial officer. Medidata offers clients wearable sensors that help track patients’ health in real life and biomarker analysis to select which ones may best respond to drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology.“This is by far the largest acquisition we’ve ever made,” Daloz said on a conference call, highlighting Dassault’s interest in the health market.Drugmakers’ CostsThe all-cash transaction values Medidata at $92.25 a share -- 17% more than Medidata’s closing price on April 18, the last trading day before Bloomberg reported Dassault’s interest in the New York-based company. Medidata shares were down 3.5% to $91.45 at 9:59 a.m. in New York. Dassault fell 1.5% to 134.45 euros in Paris.The deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement.Drugmakers faced with rising development costs are outsourcing many parts of their research and development efforts, using specialized providers of services and technology.Medidata counts most of the biggest drug companies in the world as customers, according to supply-chain data compiled by Bloomberg. It provides a cloud-based subscription service that helps medical device, diagnostic and pharmaceutical companies manage and analyze clinical trials. Its revenue more than doubled from 2013 to 2018, when it brought in $635.7 million.Dassault, with a market value of 36 billion euros ($41 billion), offers software and services for industries ranging from aerospace and defense to consumer goods. The life sciences business counts many major pharma companies among its clients.The planned acquisition, endorsed by both boards, marks the first time the French company has resorted to external funding, according to Daloz. Dassault will finance the takeover with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash.(Updates with Dassault shares in sixth paragraph.)\--With assistance from Liana Baker, Geraldine Amiel and Marie Mawad.To contact the reporters on this story: Ed Hammond in New York at email@example.com;Ruth David in London at firstname.lastname@example.org;Manuel Baigorri in Hong Kong at email@example.comTo contact the editors responsible for this story: Elizabeth Fournier at firstname.lastname@example.org, ;Giles Turner at email@example.com, Jeff Sutherland, Thomas MulierFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
France's Dassault Systemes moved to build up its life sciences presence with a $5.8 billion cash deal to buy Medidata Solutions, a U.S. firm focused on clinical trials. Dassault Systemes has been doing deals to diversify its technology and software businesses further and its agreed acquisition of Medidata, its largest, follows its purchases of companies including Trace Software and Argosim. Medidata has a market capitalisation of around $5.9 billion, Refinitiv Eikon data shows, while Dassault has a stock market value of around 36 billion euros ($41 billion).
Shares of Medidata were up 5.5% at $100 in after-hours trading. Cloud-based Medidata's software is used to help clinics manage back office operations and data, besides providing analytics tools, the report said. The Medidata deal will be Dassault's third acquisition this year.